Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Adalimumab in Crohn Disease: NCT07510191 Clinical Landscape Report 2026
15 October 2026
NCT07510191 clinical landscape for Crohn Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic human mesenchymal stem cells(University of Miami) in Alzheimer Disease: NCT07512362 Clinical Landscape Report 2026
15 October 2026
NCT07512362 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Colecalciferol in Pulmonary Disease, Chronic Obstructive: TCTR20260405002 Clinical Landscape Report 2026
15 October 2026
TCTR20260405002 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
TSL2109 in Advanced Malignant Solid Neoplasm: NCT07514065 Clinical Landscape Report 2026
15 October 2026
NCT07514065 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Fludarabine Phosphate in Recurrent Lung Small Cell Carcinoma: NCT07509034 Clinical Landscape Report 2026
15 October 2026
NCT07509034 clinical landscape for Recurrent Lung Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Omacetaxine Mepesuccinate in Prostatic Cancer: NCT07516704 Clinical Landscape Report 2026
15 October 2026
NCT07516704 clinical landscape for Prostatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lu-AF28996 in Parkinson Disease: NCT07513441 Clinical Landscape Report 2026
15 October 2026
NCT07513441 clinical landscape for Parkinson Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluticasone furoate in Pulmonary Disease, Chronic Obstructive: CTRI/2026/04/107954 Clinical Landscape Report 2026
15 October 2026
CTRI/2026/04/107954 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and developm…
9 min read
XKH-001 in Pulmonary Disease, Chronic Obstructive: NCT07519499 Clinical Landscape Report 2026
15 October 2026
NCT07519499 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Tislelizumab in Hepatocellular Carcinoma: NCT07518706 Clinical Landscape Report 2026
15 October 2026
NCT07518706 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BHB-810 in Advanced Gastric Adenocarcinoma: NCT07529808 Clinical Landscape Report 2026
15 October 2026
NCT07529808 clinical landscape for Advanced Gastric Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Hepatocellular Carcinoma: NCT07521852 Clinical Landscape Report 2026
15 October 2026
NCT07521852 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.